LEE'S PHARM (00950) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of HK$695 million, representing a 5.5% year-on-year increase. Profit attributable to owners of the company reached HK$67.185 million, up 7.5% compared to the same period last year. Earnings per share stood at HK$0.1141, and the company proposed an interim dividend of HK$0.022 per share.

According to the announcement, the revenue increase was primarily driven by robust sales performance across the group's product portfolio. Among various rare disease and specialty products, treprostinil injection "Remodulin®" achieved strong growth of 31.4%, while "Bredinin®" increased by 12.9%. In the traditional portfolio of imported products, "Fepruli®" recorded significant growth of 33.3%, once again becoming the largest contributing product after last year's transitional phase.

Products under the centralized volume-based procurement program also played an important role in driving revenue growth. Fondaparinux sodium injection "LiChangQing®" and nadroparin calcium injection "LiTengJing®" achieved growth of 18.8% and 11.3% respectively. These improved product performances supported overall revenue growth and helped offset the impact of slower sales of certain other products during the review period.